抗菌药物心脏毒性研究进展  

Progress in antimicrobials-induced cardio-toxicity

作　　者：刘金永[1,2] 葛卫红[1] 周长江[1] 

机构地区：[1]南京大学医学院附属鼓楼医院,江苏南京210008 [2]中国药科大学药学院,江苏南京210009

出　　处：《中国医院药学杂志》2014年第19期1696-1699,共4页Chinese Journal of Hospital Pharmacy

摘　　要：近年来,一些非心血管系统药物引起的心脏毒性反应正日益受到重视,如特非那定、格帕沙星、西沙比利等,因临床使用中出现严重心脏毒性而被撤市或限制使用。抗菌药物临床应用广泛,不良反应的个案报道也越来越多,其中心脏毒性反应因容易导致严重临床后果应引起临床医生和药师的重视。In recent years, cardio-toxicity induced hy non-cardiovascular system drugs is gaining more and more attention. Some drugs, such as terfenadine, grepafloxacin and cisapride , have been withdrawn from the market or restricted the clinical use for their severe cardiac toxicity. Drug-induced cardio-toxicity is considered as the most frequent cause of withdrawal or rela- beling of marketed drugs in the last decade. Antimicrobials are now used widely in clinic, there are more and more adverse drug reactions reported. Clinicians and pharmacists should pay great attention to this cardiac toxicity for it may cause severe clinical consequences.

关 键 词：抗菌药物 心脏毒性 QT间期延长 尖端扭转型室性心动过速 

分 类 号：R978[医药卫生—药品]